SG161101A1 - Pharmaceutical formulations of antineoplastic agents, in particular temozolomide processes of making and using the same - Google Patents

Pharmaceutical formulations of antineoplastic agents, in particular temozolomide processes of making and using the same

Info

Publication number
SG161101A1
SG161101A1 SG200605719-4A SG2006057194A SG161101A1 SG 161101 A1 SG161101 A1 SG 161101A1 SG 2006057194 A SG2006057194 A SG 2006057194A SG 161101 A1 SG161101 A1 SG 161101A1
Authority
SG
Singapore
Prior art keywords
pharmaceutical formulations
processes
making
same
antineoplastic agents
Prior art date
Application number
SG200605719-4A
Other languages
English (en)
Inventor
Sydney Ugwu
Vinay Radhakrishnan
Peter M Ihnat
Leonore C Witchey-Lakshmanan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27766051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG161101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of SG161101A1 publication Critical patent/SG161101A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200605719-4A 2002-02-22 2003-02-20 Pharmaceutical formulations of antineoplastic agents, in particular temozolomide processes of making and using the same SG161101A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35919802P 2002-02-22 2002-02-22

Publications (1)

Publication Number Publication Date
SG161101A1 true SG161101A1 (en) 2010-05-27

Family

ID=27766051

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200605719-4A SG161101A1 (en) 2002-02-22 2003-02-20 Pharmaceutical formulations of antineoplastic agents, in particular temozolomide processes of making and using the same

Country Status (24)

Country Link
US (9) US6987108B2 (zh)
EP (1) EP1478339B9 (zh)
JP (2) JP4077794B2 (zh)
KR (1) KR100970528B1 (zh)
CN (2) CN100346784C (zh)
AR (3) AR038535A1 (zh)
AT (1) ATE397440T1 (zh)
AU (1) AU2003213142B2 (zh)
BR (1) BRPI0307802B8 (zh)
CA (2) CA2476494C (zh)
CY (1) CY1108291T1 (zh)
DE (1) DE60321450D1 (zh)
DK (1) DK1478339T3 (zh)
ES (1) ES2307905T3 (zh)
HK (1) HK1066466A1 (zh)
MX (1) MXPA04008133A (zh)
NO (1) NO335045B1 (zh)
NZ (1) NZ534378A (zh)
PL (1) PL205936B1 (zh)
PT (1) PT1478339E (zh)
SG (1) SG161101A1 (zh)
SI (1) SI1478339T1 (zh)
WO (1) WO2003072082A1 (zh)
ZA (1) ZA200406632B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1478339T1 (sl) * 2002-02-22 2008-10-31 Schering Corp Farmacevtske formulacije antineoplastičnih sredstev, zlasti temozolomida, postopki za pripravo in uporabo le-teh
EP1746975A2 (en) * 2004-04-01 2007-01-31 Teva Pharmaceutical Industries Limited Delayed release formulations of 6-mercaptopurine
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
WO2006060464A1 (en) * 2004-12-02 2006-06-08 Schering Corporation Methods of using temozolomide formulation intrathecally in the treatment of cancers
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
EP2727936B1 (en) 2006-11-22 2016-09-07 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US20100119592A1 (en) * 2006-12-08 2010-05-13 Bruce Michael Frankel Cytarabine for treatment of glioma
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
BRPI0823416A2 (pt) * 2007-05-08 2015-06-16 Schering Corp Métodos de tratamento usando formulações intravenosas compreendendo temozolomida.
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
CN101467967B (zh) * 2007-12-29 2012-05-23 北京京卫燕康药物研究所有限公司 用于静脉和脑内注射的两元溶液型制剂
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
CN101559037B (zh) * 2008-04-16 2013-01-30 北京京卫燕康药物研究所有限公司 用于静脉和脑内注射的两元溶液型制剂
WO2009128955A1 (en) * 2008-04-18 2009-10-22 Teva Pharmaceutical Industries Ltd. Treatment of inflammatory bowel disease with 6-mercaptopurine
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
AR066943A1 (es) * 2008-06-10 2009-09-23 Eriochem Sa Una composicion farmaceutica de melfalano
WO2010005580A2 (en) 2008-07-10 2010-01-14 Angion Biomedica Corp. Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
CA2883255C (en) 2008-09-30 2016-10-25 Shaw Industries Group, Inc. Recycled polethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same
MX2022000193A (es) 2008-09-30 2022-03-02 Shaw Ind Group Inc Composiciones de tereftalato de polietileno reciclado, fibras y articulos producidos a partir de las mismas, y metodos para producirlas.
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2396000A1 (en) * 2009-02-11 2011-12-21 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
WO2011036676A2 (en) 2009-09-23 2011-03-31 Ashwini Nangia Stable cocrystals of temozolomide
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
CN101869551B (zh) * 2010-06-28 2012-04-18 江苏奥赛康药业股份有限公司 一种替莫唑胺冻干制剂
CN102342931B (zh) * 2010-07-29 2014-04-23 江苏恒瑞医药股份有限公司 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法
CN101984968A (zh) * 2010-10-29 2011-03-16 北京润德康医药技术有限公司 抗肿瘤剂替莫唑胺的药物制剂制备方法
CN102659789B (zh) * 2011-04-27 2014-10-15 四川科瑞德凯华制药有限公司 一锅法制备替莫唑胺的方法及替莫唑胺的精制方法
CA3024230C (en) * 2011-04-28 2022-10-18 Oncopeptides Ab Lyophilized preparation of cytotoxic dipeptides
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
CN102949351B (zh) * 2011-08-16 2015-05-13 上海汇伦生命科技有限公司 一种替莫唑胺冻干制剂的制备方法
CN102688202B (zh) * 2012-06-07 2013-08-14 北京莱瑞森医药科技有限公司 一种替莫唑胺冻干制剂
US8974811B2 (en) 2013-03-14 2015-03-10 Hikma Pharmaceuticals Stabilized pharmaceutical formulations comprising antineoplastic compounds
CN104274412A (zh) * 2013-07-01 2015-01-14 北京恒瑞康达医药科技发展有限公司 一种含有替莫唑胺、其药学上可接受的盐或其他衍生物的药物制剂
CN103432085A (zh) * 2013-08-19 2013-12-11 南京海纳医药科技有限公司 一种含氨基酸增溶剂的替莫唑胺冻干制剂及其制备方法
LT2865391T (lt) 2013-10-22 2017-11-27 Medac Gesellschaft für klinische Spezialpräparate mbH Liofilizuotos kompozicijos, turinčios mitomiciną c, gamybos būdas
WO2015193477A1 (en) * 2014-06-20 2015-12-23 Syddansk Universitet Auger electron therapy for glioblastoma
MA40428A (fr) * 2014-08-14 2016-02-18 L E A F Holdings Group Llc Médicament à affinité encapsulé dans un liposome
CA2971868C (en) 2015-01-14 2023-04-04 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
WO2017066619A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
CN107334766A (zh) * 2016-05-02 2017-11-10 双键医药品股份公司 包含替莫唑胺的稳定的抗肿瘤药物组合物，以及该组合物的制备方法
JP6706988B2 (ja) * 2016-07-20 2020-06-10 日本化薬株式会社 ボルテゾミブを含有する医薬組成物
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
CN107213123A (zh) * 2017-07-23 2017-09-29 南京正宽医药科技有限公司 一种注射用盐酸氨溴索及其制备方法
US20190216823A1 (en) * 2018-01-12 2019-07-18 Hyloris Developments Sa Methylprednisolone pharmaceutical suspension
CN114026085A (zh) 2019-04-11 2022-02-08 安吉昂生物医药公司 (e)-3-[2-(2-噻吩基)乙烯基]-1h-吡唑的固体形式
WO2021108601A1 (en) * 2019-11-25 2021-06-03 The Johns Hopkins University Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors
WO2021229442A1 (en) 2020-05-12 2021-11-18 Shorla Pharma Ltd Stable formulations of temozolomide for oral administration
WO2024071464A1 (ko) * 2022-09-27 2024-04-04 (주)바이오솔릭스 말레이트 금속염을 포함하는 항암용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675183A (en) * 1984-04-28 1987-06-23 Kwoya Hakko Kogyo Co., Ltd. Method for solubilization of interferon
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
JPS63313721A (ja) * 1987-06-17 1988-12-21 Teisan Seiyaku Kk 速溶性の注射用組成物
SU1479049A1 (ru) * 1987-07-01 1989-05-15 Научно-производственное объединение "Биолар" Способ получени концентрата водорастворимых фосфолипидов
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
JP2977236B2 (ja) * 1990-07-20 1999-11-15 株式会社東芝 音声合成装置
US5268368A (en) * 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
CA2153775C (en) * 1993-01-14 2000-11-14 John Colin Baer Potentiation of temozolomide in human tumour cells
DE4331147A1 (de) * 1993-09-14 1995-03-16 Nycomed Arzneimittel Gmbh Intravenös verabreichbare, wäßrige Lösung
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
IL138221A0 (en) 1998-03-26 2001-10-31 Schering Corp Formulations for protection of peg-interferon alpha conjugates
US5972912A (en) 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
MXPA02006240A (es) * 1999-12-24 2003-01-28 Bayer Ag Nuevas imidazo[1,3,5,) triazinonas y su uso.
SI1478339T1 (sl) 2002-02-22 2008-10-31 Schering Corp Farmacevtske formulacije antineoplastičnih sredstev, zlasti temozolomida, postopki za pripravo in uporabo le-teh
CN101098696A (zh) 2004-11-09 2008-01-02 先灵公司 基于患者mgmt水平来治疗癌症的替莫唑胺的改进给药方案

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675183A (en) * 1984-04-28 1987-06-23 Kwoya Hakko Kogyo Co., Ltd. Method for solubilization of interferon
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers

Also Published As

Publication number Publication date
US6987108B2 (en) 2006-01-17
US8623868B2 (en) 2014-01-07
ZA200406632B (en) 2005-11-30
CA2662899A1 (en) 2003-09-04
AU2003213142A1 (en) 2003-09-09
AR064722A2 (es) 2009-04-22
US8076335B2 (en) 2011-12-13
AR084868A2 (es) 2013-07-10
ATE397440T1 (de) 2008-06-15
CN100346784C (zh) 2007-11-07
KR20040085196A (ko) 2004-10-07
US20190336495A1 (en) 2019-11-07
EP1478339B1 (en) 2008-06-04
ES2307905T3 (es) 2008-12-01
US20140088166A1 (en) 2014-03-27
US20040043001A1 (en) 2004-03-04
US20120053219A1 (en) 2012-03-01
CN101172104A (zh) 2008-05-07
EP1478339B9 (en) 2009-08-19
CY1108291T1 (el) 2014-02-12
US20060122163A1 (en) 2006-06-08
SI1478339T1 (sl) 2008-10-31
BR0307802A (pt) 2004-12-21
CN101172104B (zh) 2013-04-03
JP2005518434A (ja) 2005-06-23
CA2476494C (en) 2010-04-27
NO335045B1 (no) 2014-09-01
PL372319A1 (en) 2005-07-11
NO20043961L (no) 2004-09-21
PL205936B1 (pl) 2010-06-30
AU2003213142B2 (en) 2005-11-10
US20180078546A1 (en) 2018-03-22
US20100331382A1 (en) 2010-12-30
HK1066466A1 (en) 2005-03-24
US7786118B2 (en) 2010-08-31
US7674790B2 (en) 2010-03-09
DE60321450D1 (de) 2008-07-17
CN1635871A (zh) 2005-07-06
US20160082005A1 (en) 2016-03-24
JP4077794B2 (ja) 2008-04-23
BRPI0307802B8 (pt) 2021-05-25
US20090176852A1 (en) 2009-07-09
AR038535A1 (es) 2005-01-19
MXPA04008133A (es) 2004-11-26
JP2008031186A (ja) 2008-02-14
PT1478339E (pt) 2008-09-05
BRPI0307802B1 (pt) 2018-11-27
CA2476494A1 (en) 2003-09-04
DK1478339T3 (da) 2008-08-25
EP1478339A1 (en) 2004-11-24
WO2003072082A1 (en) 2003-09-04
NZ534378A (en) 2006-10-27
JP4785816B2 (ja) 2011-10-05
KR100970528B1 (ko) 2010-07-16

Similar Documents

Publication Publication Date Title
SG161101A1 (en) Pharmaceutical formulations of antineoplastic agents, in particular temozolomide processes of making and using the same
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
MY127369A (en) Quinazoline derivatives
WO2005065646A3 (en) Novel drug compositions and dosage forms
PL378051A1 (pl) Szybko działająca kompozycja farmaceutyczna
GEP20105024B (en) Fused heterocyclic compound
AU2002331391A1 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
WO2005028479A3 (en) Hiv replication inhibiting purine derivatives
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
AR018143A1 (es) Formulacion para preparar un comprimido de desintegracion rapida, comprimidos de desintegracion rapida, especialmente comprimidos de desintegracionrapida en la boca
RS50008B (sr) Antifungalna oralna kompozicija koja sadrži itrakonazol i postupak za dobijanje iste
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
BR0314687A (pt) Formulações farmacêuticas sólidas que compreendem telmissartano
WO2004026836A8 (en) 1-pyridin-4-yl-urea derivatives
ZA200709296B (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycolotonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
HUP0401811A2 (hu) Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
WO2004014868A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
WO2003032947A3 (en) A method for preparing liposome formulations with a predefined release profile
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
CA2437785A1 (en) Hiv inhibiting pyrazinone derivatives
WO2005020959A3 (en) Novel drug compositions and dosage forms of topiramate
WO2005065648A3 (en) Novel drug compositions and dosage forms of topiramate
FR12C0064I2 (fr) Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale
TW200510370A (en) Urea derivatives